- Home
- RGNX vs REPL Comparison
RGNX vs REPL Comparison
Compare RGNX & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- REPL
- Stock Information
- Founded
- RGNX 2008
- REPL 2015
- Country
- RGNX United States
- REPL United States
- Employees
- RGNX N/A
- REPL N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- RGNX Health Care
- REPL Health Care
- Exchange
- RGNX Nasdaq
- REPL Nasdaq
- Market Cap
- RGNX 661.2M
- REPL 547.0M
- IPO Year
- RGNX 2015
- REPL 2018
- Fundamental
- Price
- RGNX $13.08
- REPL $10.19
- Analyst Decision
- RGNX Strong Buy
- REPL Buy
- Analyst Count
- RGNX 7
- REPL 9
- Target Price
- RGNX $30.00
- REPL $10.88
- AVG Volume (30 Days)
- RGNX 602.9K
- REPL 8.7M
- Earning Date
- RGNX 11-06-2025
- REPL 11-07-2025
- Dividend Yield
- RGNX N/A
- REPL N/A
- EPS Growth
- RGNX N/A
- REPL N/A
- EPS
- RGNX N/A
- REPL N/A
- Revenue
- RGNX $155,782,000.00
- REPL N/A
- Revenue This Year
- RGNX $198.02
- REPL N/A
- Revenue Next Year
- RGNX $2.67
- REPL N/A
- P/E Ratio
- RGNX N/A
- REPL N/A
- Revenue Growth
- RGNX 74.95
- REPL N/A
- 52 Week Low
- RGNX $5.04
- REPL $2.68
- 52 Week High
- RGNX $13.93
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- RGNX 57.58
- REPL 76.27
- Support Level
- RGNX $12.66
- REPL $7.69
- Resistance Level
- RGNX $13.93
- REPL $10.85
- Average True Range (ATR)
- RGNX 0.69
- REPL 0.70
- MACD
- RGNX -0.05
- REPL 0.43
- Stochastic Oscillator
- RGNX 57.85
- REPL 89.86
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.